MagForce AG

  • WKN: A0HGQF
  • ISIN: DE000A0HGQF5
  • Land: Deutschland

Nachricht vom 06.02.2019 | 09:30

MagForce AG: Newly launched 'NanoTherm(R) Therapy School' kicks off with successful first training session


DGAP-Media / 06.02.2019 / 09:30

MagForce AG: Newly launched 'NanoTherm(R) Therapy School' kicks off with successful first training session

  • MagForce introduces practice-oriented, unique, multifaceted application training for the use of NanoTherm Therapy in treating brain tumors
  • Training concept developed in close partnership with leading experts Prof. Dr. Walter Stummer, PD Dr. Dr. Oliver Grauer, University Hospital Münster, and PD Dr. Johannes Wölfer, Hufeland Klinikum GmbH Mühlhausen

Berlin, Germany and Nevada, USA, February 06, 2019 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, is pleased to report the successful start of its newly launched NanoTherm(R) Therapy School series, a comprehensive application training series consisting of three consecutive modules to certify surgeons in the use of the Company's innovative NanoTherm technology. The first session, "Module A - the basics", took place end of January, 2019 in Berlin.

Targeted towards medical professionals working in the field of neuro-oncology, the NanoTherm(R) Therapy School series aims at introducing participants to the theoretical knowledge and practical techniques required to successfully apply MagForce's NanoTherm technology for the treatment of brain tumors. In practicising their skills with human specimens, participants are able to familiarize themselves with the procedures and device usages in a stress-free environment under largely real operating conditions.

The NanoTherm(R) Therapy School is designed in three consecutive modules allowing participants to gain knowledge and understanding of the NanoTherm technology starting from basic application techniques (nanopasting) and building to advanced techniques and more experimental application forms in the final module. The practical section of the course is complemented by lectures on directly relevant aspects of Nano Therm therapy, as well as sample preparation and surgical videos. The equipment and facilities used during the course meet the requirements of today's state of the art surgical equipment.

The training concept of NanoTherm(R) Therapy School was developed in close collaboration with Prof. Dr. Walter Stummer, PD Dr. Dr. Oliver Grauer, University Hospital Münster, and PD Dr. Johannes Wölfer, Hufeland Klinikum GmbH Mühlhausen, drawing on their long-standing experience in the treatment of brain tumor patients with NanoTherm therapy. The course is supervised with a ratio of three students to one lecturer and one technician, ensuring maximum learning success.

"Simulation-based medical education enables knowledge and skill acquirement in a safe, educational orientated and efficient environment. Becoming acquainted with a new treatment method in a stress-free yet largely realistic setting is a great way to introduce physicians to a new treatment option and is key to ensuring that patients will receive the highest quality of treatment", said Prof. Dr. Walter Stummer, Director of the Department of Neurosurgery at the University Hospital Münster.

Prof. Dr. med. habil. Jan-Peter Warnke, Director of the Department of Neurosurgery at the Chefarzt, Paracelcus Clinic Zwickau, participant of the Module A, added "Innovation is extremely important in medicine and has served our patients well. Obtaining the appropriate training in new technologies and techniques is a vital part of adopting these advances into our standard treatment regimens. Practical trainings such as MagForce's NanoTherm(R) Therapy School are therefore very welcomed as they allow neurosurgeons to ease into the method while developing the necessary skills. The mixture of academic and practical experience paired with the instructors' and speakers' long-standing experience with the technique is what sets this course apart. Embracing new methods of teaching advanced technology helps bridge the learning gap from invention to patient usage."

For more information about NanoTherm Therapy(R) School, please contact:
Dipl.-Ing. Tobias Hanitsch (thanitsch@magforce.com)
Marcel Pilz (mpilz@magforce.com)

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com.
Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list

Disclaimer
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Contact:
Barbara von Frankenberg
Vice President
Communications & Investor Relations
T +49-30-308380-77
E-Mail: bfrankenberg@magforce.com 


End of Media Release


Issuer: MagForce AG


06.02.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Interview im Fokus

„Im europäischen Spitzenfeld der Private-Equity-Liga“

Die Münchner Private-Equity-Gesellschaft Mutares (ISIN: DE000A2NB650) ist mit bereits fünf Akquisitionen in 2020 erneut mit einem hohen Wachstumstempo unterwegs. Im Exklusivinterview mit Financial.de verraten die Vorstände Robin Laik (CEO) und Johannes Laumann (CIO), wie man sich bei den jüngsten Deals gegen die Konkurrenz durchgesetzt hat, wie man einen Return auf das eingesetzte Kapital von 7 bis 10 erreichen will und warum sich Mutares-Aktionäre auch für 2020 auf eine attraktive Dividende freuen dürfen.

Event im Fokus

Fachkonferenz Beteiligungsgesellschaften, 15.07.2020

Fachkonferenz Consumer / Leisure, 16.07.2020

Die Konferenzen finden aufgrund der aktuellen Situation nicht in den Räumen der Börse München statt, sondern als Online-Konferenz.

GBC-Fokusbox

Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.

Aktuelle Research-Studie

wallstreet:online AG

Original-Research: wallstreet:online AG (von GBC AG): Kaufen

13. Juli 2020